Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 2,006 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Discrete Clear all

Conditions: HIV Infections, Electronic Health Record, Primary Health Care
Interventions: EMC2 PrEP Educational Tool, Discrete Scheduling of a Dedicated PrEP Visit; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Volunteers
Interventions: Sequence 1: PCI-32765, Sequence 2: PCI-32765, Sequence 3: PCI-32765, Sequence 4: PCI-32765, Sequence 5: PCI-32765; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Healthy Volunteers
Interventions: Avatrombopag maleate 40 mg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Pharmacokinetics, Solid Tumor, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms
Interventions: Boserolimab, Pembrolizumab, Pemetrexed, Carboplatin, Nab-paclitaxel; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 3
States / cities: Mobile, Alabama • Sarasota, Florida • Germantown, Tennessee

Conditions: Type 2 Diabetes Mellitus
Interventions: thiapalmitate tracer, Saline, Insulin; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Major Depressive Disorder
Interventions: TMS: single session intermittent theta burst stimulation (iTBS) to dorsomedial prefrontal target in individuals with major depressive disorder, via MagVenture MagPro R30 device / Cool-DB80 A/P coil, SHAM (inactive) TMS stimulation; Device
Lead sponsor: San Francisco Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Community-Acquired Staphylococcus Aureus
Interventions: Routine Measures Group, Bleach Bath Group (Bleach plus routine measures); Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 3 Months to 18 Years
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Leukemia, Lymphoma
Interventions: Total Lymphoid Irradiation, Fludarabine, Cyclophosphamide, Thiotepa, Melphalan, HPC,A Infusion, TC-NK Infusion, G-CSF, Mesna, CliniMACS, Mycophenolate mofetil; Radiation · Drug · Biological + 1 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Myasthenia Gravis
Interventions: Rituximab, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 90 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 26
States / cities: Birmingham, Alabama • Davis, California • Los Angeles, California + 22 more

Conditions: Healthcare Worker, Hepatitis B Vaccine, Nonresponder
Interventions: Recombinant hepatitis B vaccine with CpG adjuvant; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cannabis Dependence
Interventions: Biospecimen Collection, Cannabis sativa Extract, Nicotine, Placebo Administration, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Ovarian Cancer
Interventions: High intensity interval exercise, Attention control; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Androgenetic Alopecia
Interventions: Platelet rich plasma; Procedure
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 95 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Irvine, California

Conditions: Non-hodgkin Lymphoma
Interventions: CD38-SADA:177Lu-DOTA Complex; Drug
Lead sponsor: Y-mAbs Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 6
States / cities: Scottsdale, Arizona • Duarte, California • Grand Rapids, Michigan + 3 more

Conditions: Corneal Pain, Chronic Pain, Neuropathic Pain
Interventions: Transcranial Direct Current Stimulation (tDCS); Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: counseling intervention, questionnaire administration, psychosocial assessment and care, quality-of-life assessment; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2023
U.S. locations: 2
States / cities: New York, New York

Conditions: Diet, Healthy
Interventions: Protein isolate; Dietary Supplement
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Immune Surveillance
Interventions: Probiotic Agent; Dietary Supplement
Lead sponsor: Natural Immune Systems Inc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Klamath Falls, Oregon

Conditions: Arthritis, Rheumatoid
Interventions: BI 695500, Rituxan®, MabThera®; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 54
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 48 more

Conditions: Parkinson Disease
Interventions: GM1 ganglioside, Placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 39 Years to 85 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Volunteers
Interventions: VRG50635, Placebo; Drug
Lead sponsor: Verge Genomics; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Isolated Focal Hand Dystonia
Interventions: Transcranial Magnetic Stimulation (TMS); Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN)
Interventions: atrasentan; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Depression, Suicidal Ideation, Suicidal Impulses
Interventions: Intranasal Ketamine, Intranasal Saline Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

An Electronic Health Record-based Approach to Increase PrEP Knowledge and Uptake: the EMC2 PrEP Strategy

A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765

A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal

Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

A Novel Positron Emission Tomography (PET) Approach to Measuring Myocardial Metabolism

Using Electrophysiology to Index Non-invasive Brain Stimulation Effects on Reward System Functioning in Depression

Prevention of Recurrent Infections Caused by Community Acquired Staphylococcus Aureus (CA-SA) in Children

Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy

BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis

HepB-CpG Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders

Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream

Exercise Preconditioning in Ovarian Cancer

The Utility of Platelet Rich Plasma in Hair Loss

Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Effects of Transcranial Direct Current Stimulation (tDCS) in Chronic Corneal Pain

Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions

Impact of Protein Source on Gut Health

Acute Immune Modulation by Probiotic Strain

Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

GM1 Ganglioside Effects on Parkinson's Disease

A Study of VRG50635 in Healthy Volunteers

Accelerated TMS for Focal Hand Dystonia

Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)

Emergency Ketamine Treatment of Suicidal Ideation